{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=30", "query": { "condition": "DNA", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 3219, "total_pages": 322, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T02:24:56.678Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01971385", "title": "Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Herpes Labialis" ], "interventions": [ { "name": "Squaric Acid solution", "type": "DRUG" }, { "name": "Placebo solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 54, "start_date": "2013-10", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01971385" }, { "nct_id": "NCT05673018", "title": "Galleri® in the Medicare Population.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Multi-Cancer Early Detection Test (Galleri®)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "GRAIL, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 50000, "start_date": "2024-07-12", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 72, "location_summary": "Fort Smith, Arkansas • Auburn, California • Davis, California + 51 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Davis", "state": "California" }, { "city": "Elk Grove", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05673018" }, { "nct_id": "NCT03199040", "title": "Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "TNBC - Triple-Negative Breast Cancer", "Triple-negative Breast Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "TDS-IM system (Inchor Medical Systems)", "type": "DEVICE" }, { "name": "Peripheral blood draw", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2019-07-23", "completion_date": "2023-05-01", "has_results": true, "last_update_posted_date": "2024-05-28", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03199040" }, { "nct_id": "NCT01158274", "title": "RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "AIDS-related Small Noncleaved Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "HER2-negative Breast Cancer", "HIV-associated Hodgkin Lymphoma", "Intraocular Lymphoma", "Male Breast Cancer", "Nodal Marginal Zone B-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Rectal Cancer", "Recurrent Small Lymphocytic Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Colon Cancer", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Rectal Cancer", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Rectal Cancer", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-07", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01158274" }, { "nct_id": "NCT03300882", "title": "PREDICT Cytomegalovirus (CMV)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Transplant" ], "interventions": [ { "name": "Procedure", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2017-10-31", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Durham, North Carolina • Cleveland, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300882" }, { "nct_id": "NCT00156559", "title": "MMR and Varicella Vaccine in Premature Infants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chickenpox", "Rubella", "Rubeola", "Mumps" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "16 Months", "sex": "ALL", "summary": "12 Months to 16 Months" }, "enrollment_count": 32, "start_date": "2004-01", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2015-09-17", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156559" }, { "nct_id": "NCT03913559", "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 5, "start_date": "2019-05-14", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 2, "location_summary": "San Diego, California • Memphis, Tennessee", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03913559" }, { "nct_id": "NCT04232280", "title": "Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Infection" ], "interventions": [ { "name": "mRNA-1647", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 315, "start_date": "2020-01-09", "completion_date": "2023-01-04", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 9, "location_summary": "Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04232280" }, { "nct_id": "NCT01474720", "title": "Zostavax in Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Zostavax vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oklahoma Medical Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2011-11", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01474720" }, { "nct_id": "NCT07254208", "title": "A Long-term Observational Study in Participants Who Have Received PBGENE-HBV", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic HBV Infection" ], "interventions": [ { "name": "PBGENE-HBV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precision BioSciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "19 Years to 80 Years" }, "enrollment_count": 45, "start_date": "2025-12-25", "completion_date": "2040-06", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-31T02:24:56.678Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07254208" } ] }